Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reliability of bedside ABO testing before transfusion.

Virginie Migeot1, Isabelle Ingrand, Louis Rachid Salmi

  • 1Faculty of Medicine and Pharmacy, University Institute of Public Health, 34 rue du Jardin des Plantes, F-86005 Poitiers, France. virginie.migeot@univ-poitiers.fr

Transfusion
|November 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening tools for ruling out mood and anxiety disorders in adults in primary care: a rapid systematic review.

BMC primary care·2025
Same author

Detection of Endocrine Disruptors in Human Placenta: A Pilot Study on Exposure and Histopathological Findings.

Therapeutic drug monitoring·2025
Same author

Correlation Between Health Literacy and Tacrolimus Variability in Solid Organ Transplant Recipients.

Clinical transplantation·2025
Same author

Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2025
Same author

Sante publique (Vandoeuvre-les-Nancy, France)·2025
Same author

COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study.

BMC cancer·2025
Same journal

Investigation of the preanalytical stability of blood donor samples.

Transfusion·2026
Same journal

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
See all related articles

Both new and popular bedside blood transfusion compatibility tests showed high error rates. While experts favored the new Vu-Test device, neither fully eliminated transfusion errors, highlighting the need for improved methods.

Area of Science:

  • Transfusion Medicine
  • Clinical Pathology
  • Patient Safety

Background:

  • Bedside transfusion compatibility testing is prone to errors due to technique and user performance issues.
  • Previous studies indicate significant challenges in accurate bedside testing.
  • An evaluation of a new device was warranted to address these concerns.

Purpose of the Study:

  • To evaluate the error rate of a new ready-to-use bedside compatibility test device (Vu-Test).
  • To compare the Vu-Test device with the widely used Safety-Test ABO card in France.
  • To assess user performance and device effectiveness in clinical settings.

Main Methods:

  • Nurses performed cross-matches using both Safety-Test ABO and Vu-Test on paired blood samples.
  • Tests included agglutination detection, compatibility interpretation, and transfusion decisions.

Related Experiment Videos

  • Independent expert review of test results and user feedback were collected.

    • Main Results:

    • Error-free testing rates were 70.9% for Safety-Test ABO and 66.0% for Vu-Test, with no significant difference between devices.
    • The risk of erroneous agglutination detection did not differ significantly between the two devices.
    • Expert reviewers found the Vu-Test device to be significantly better than Safety-Test ABO.

    Conclusions:

    • Both tested bedside compatibility devices exhibited high error rates.
    • While experts favored the Vu-Test, it did not significantly reduce overall errors compared to Safety-Test ABO.
    • Nurse experience was a significant factor in reducing errors, underscoring the importance of training.